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We have previously shown that the C-glycoside analog of α-galactosylceramide (α-GalCer), α-C-GalCer, displays a superior
inhibitory activity against the liver stages of the rodent malaria parasite Plasmodium yoelii than its parental glycolipid, α-GalCer. In
this study, we demonstrate that NK cells, as well as IL-12, are a key contributor for the superior activity displayed by α-C-GalCer.
Surprisingly, the diminished production of Th2 cytokines, including IL-4, by α-C-GalCer has no aﬀect on its superior therapeutic
activity relative to α-GalCer. Finally, we show that the in vivo administration of α-C-GalCer induces prolonged maturation of
dendritic cells (DCs), as well as an enhanced proliferative response of mouse invariant Vα14 (Vα14i) NKT cells, both of which
may also contribute to some degree to the superior activity of α-C-GalCer in vivo.
1.Introduction
Malaria remains one of the most serious and prevalent
infectious diseases in the world. Approximately 500 million
people acquire the disease annually, which leads to 2-3
million deaths per year. Malaria is caused by species of
Plasmodium,anapicomplexanparasitetransmittedinnature
by mosquito vectors of the genus Anopheles. The life cycle
of Plasmodium is the same no matter what the species,
consisting of both sexual stages that occur in the mosquito
vector and asexual stages that occur in a vertebrate host. The
asexualstagescanbedividedintothepre-erythrocyticstages,
which consist primarily of developmental events occurring
within infected hepatocytes (the so-called liver stages), and
the erythrocytic, or blood, stages, which occur in red blood
cells, and which result in the signs and symptoms of malaria
[1].
Numerous studies have shown that T cells, including
CD8+T cells, CD4+T cells, γδ-T cells, and natural killer
(NKT) cells play a key role in the immune response to
the pre-erythrocytic stages of Plasmodium [2]. Of recent
interest is the role of NKT cells, a unique population of
lymphocytes that coexpress markers of NK cells along with
a semi-invariant TCR. In mice, the TCR of most NKT cells
consists of an invariant Vα14Jα18 α chain paired with a
variable set of β chains consisting primarily of Vβ8.2, Vβ7,
or Vβ2. This invariant Vα14 TCR (Vα14i) enables NKT cells
to recognize the MHC class I–like molecule CD1d, which is
capable of presenting hydrophobic molecules such as lipids
and hydrophobic peptides to Vα14i NKT cells [3, 4].
To date, only a few compounds have been shown to
bind CD1d and stimulate Vα14i NKT cells. Of these, the
prototype molecule is α-galactosylceramide (α-GalCer), a
glycolipid originally derived from a marine sponge extract.
Previously, using a murine malaria model, we showed that
α-GalCer is able to directly mediate protection to the
pre-erythrocytic stages of malaria in a manner dependent
on iNKT cells, CD1d, and IFN-γ [5]. More recently, we
demonstrated that a structurally similar C-glycoside analog
of α-GalCer, α-C-galactosylceramide (α-C-GalCer), is also
capable of mediating protection to the pre-erythrocytic
stages of malaria in a manner dependent on Vα14i NKT2 Journal of Biomedicine and Biotechnology
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Figure 1: Structural comparison between α-C-GalCer and α-GalCer showing the main diﬀerences between the two molecules. Glycoside
CH2 is nonpolar and hydrophobic; it repels hydrogen bond donors. In contrast, glycoside oxygen is polar, and the electron pairs can form
hydrogen bonds with N–H or O–H donors.
cells, CD1d, and IFN-γ [6]. Moreover, we showed that α-C-
GalCer, which diﬀers from α-GalCer only in the identity of
the chemical group involved in the glycosidic linkage of the
galactose and ceramide moieties of the molecule (Figure 1),
exhibits a much more potent and longer lasting antimalarial
eﬀect than α-GalCer, an eﬀect which appears to stem from
prolonged downstream IFN-γ production by NK cells, and
which requires the presence of IL-12 [6]. In a follow-up
study, we showed that CD8α+ dendritic cells (DCs) are the
cells responsible for producing this IL-12 in response to
glycolipid injection, and that depletion of these cells results
in attenuated downstream IFN-γ production by NK cells [7].
Our ﬁndings were corroborated by a more recent study by
Fujii et al., which demonstrated that α-C-GalCer induces
higher degree of DC activation than α-GalCer [8].
In the present study, we further examine the physiologic
mechanism underlying the superior antimalarial activity of
α-C-GalCer. We ﬁnd that the mechanism involves IL-12, NK
cells and DCs, but not the Th2 cytokines IL-4 and IL-10, nor
the TCRβ used by the Vα14i NKT cells.
2.MaterialsandMethods
2.1. Chemicals. α-galactosylceramide [(2 S,3 S,4 R)-1 -O-(α-
D-galactopyranosyl)-2-(N-hexacosanoylamino)-1,3,4-octa-
decanetriol] was synthesized by Kirin Brewery (Gumma,
Japan). The stock solution was dissolved in a 0.5%
polysorbate-20 (Nikko Chemical, Tokyo), 0.9% NaCl
solution at a concentration of 200μg/mL, and diluted in PBS
to the desired concentration just prior to injection into mice.
α-C-galactosylceramide [(2 S,3 S,4 R)-1 -CH2-(α-D-gal-
actopyranosyl)-2-(N-hexacosanoylamino)-3,4-nonadecane-
diol] was synthesized as described previously [9]. The stock
solution, originally dissolved to a concentration of 1mg/mL
in 100% DMSO, was diluted to a working concentration
of 200μg/mL in a 0.5% polysorbate-20 (Nikko Chemical,
Tokyo), 0.9% NaCl solution. Before injection into mice,
the working solution was further diluted to the desired
concentration in PBS.
2.2.Mice. Six-toeight-week-oldfemaleBALB/candC57BL/
6 mice were purchased from the National Cancer Institute
(Bethesda, MD). IL-12p40-deﬁcient mice of BALB/c and
C57BL/6 backgrounds, IL-4-deﬁcient mice of BALB/c back-
ground, and IL-10-deﬁcient mice of C57BL/6 background
wereallpurchasedfromtheJacksonLaboratory(BarHarbor,
ME).
2.3. Injections. For glycolipid treatments, mice were injected
intraperperitoneally with 1μg of either α-GalCer or α-C-
GalCer. In some experiments, treated and untreated mice
were challenged with live P. yoelii sporozoites 3 days later.
2 . 4 .P a r a s i t e sa n dT h e i rU s ef o rC h a l l e n g e .P .y o e l i i(17XNL
strain) was maintained by alternate cyclic passages in
Anopheles stephensi mosquitoes and Swiss Webster mice.
Sporozoites obtained from dissected salivary glands of
infected mosquitoes 2 weeks after their infective blood meal
were used for challenge of the mice. Challenge of mice to
determine the development of liver-stage malaria infection
was performed by an intravenous injection of 10,000 viable
sporozoites into the tail vein. The outcome of the challenge
was determined 40–42 hours later by measuring the parasite
burden in the livers of the mice using a quantitative real-time
RT-PCR method [10].
2.5. Culture Medium. DMEM media supplemented with
10% heat-inactivated fetal calf serum (FCS) (DMEM-
10) and RPMI 1640 media supplemented with 10%
heat-inactivated FCS (RPMI-10) were used in all exper-
iments involving cell suspensions. In addition to FCS,
the media were supplemented with 100IU/mL of peni-
cillin/streptomycin, 10μg/mL of gentamicin, 10 mM HEPES
buﬀer, 50μMo fβ-mercaptoethanol, 2mM of L-glutamine,
1mMofsodiumpyruvate,and100μMofnonessentialamino
acids. All reagents were obtained from GIBCO (Carlsbad,
CA) except FCS, which was obtained from HyClone (Logan,
UT).
2.6. Determination of Malaria Liver Stage Development. The
degree of liver stage development in challenged mice was
determined by quantifying the amount of P. yoelii-speciﬁc
18S ribosomal RNA (rRNA) molecules in the livers of theJournal of Biomedicine and Biotechnology 3
mice by way of a recently developed real-time RT-PCR
technique [10]. 40–42 hours after sporozoite challenge, livers
from challenged mice were dissected and homogenized in
4mL/liver of denaturing solution (4M guanidium thio-
cyanate, 25mM sodium citrate pH 7.0, 0.5% sarcosyl, 0.1M
β-mercaptoethanol) using a PowerGen 125 biohomogenizer
(Fisher, Pittsburgh, PA). RNA was then puriﬁed from 600μL
aliquots of the homogenates using the method developed
by Chomczynski and Sacchi [11]. 2μg samples of the
RNA were then reverse-transcribed, and aliquots of the
resulting complementary DNA (cDNA) (133ng) were used
for real-time PCR ampliﬁcation of P. yoelii 18S rRNA
sequences. This ampliﬁcation was performed in a GeneAmp
5700 Sequence Detection System (PE Applied Biosystems,
Foster City, CA). For this purpose, we used primers
5 -GGGGATTGGTTTTGACGTTTTTGCG-3  (54nM) and
5 -AAGCATTAAATAAAGCGAATACATCCTTAT-3 (60nM)
together with the double-stranded DNA (dsDNA)-speciﬁc
dye SYBR Green I incorporated into the PCR reaction
buﬀer (PE Biosystems, Foster City, CA) in order to detect
the PCR product generated. The temperature proﬁle of the
reaction was 95◦C for 10 minutes followed by 40 cycles of
denaturationat95◦Cfor15secondsandannealing/extension
at 60◦Cf o r1m i n u t e .
2.7. Isolation of Splenocytes and Intrahepatic Lymphocytes
from Mice. Mouse splenocytes were prepared by gently
grinding spleens between the frosted ends of two microscope
slides in a petri dish containing 10mL of DMEM-10 or
RPMI-10 medium. The resulting cell suspension was ﬁltered
through nylon mesh, pelleted, and incubated with 5mL
of ACK lysis buﬀer for 5 minutes at room temperature
to remove red blood cells. The cells were then washed
three times with DMEM-10 or RPMI-10 medium, ﬁltered
once more through nylon mesh, and counted using a
hemocytometer and tryphan blue (GIBCO, Carlsbad, CA).
Intrahepatic lymphocytes from mice were prepared
by grinding livers in a steel mesh screen using a 3mL
syringe pestle, and ﬁltering the resulting homogenate into
a 50mL tube using 45mL of Hank’s Balanced Salt Solution
(HBSS) (GIBCO, Carlsbad, CA). After centrifugation of the
homogenate, the pellet was resuspended in 45mL of a 35%
Percoll (Amersham Biosciences, Piscataway, NJ) solution
(29.1mL HBSS, 14.2mL Percoll, 1.6mL 10X PBS, 200U
heparin), and centrifuged at 500g for 10 minutes at 20
degrees Celsius. The resulting high-density liver lymphocyte
pellet was resuspended in 5mL of ACK lysis buﬀer for 5
minutes at room temperature to remove red blood cells,
and then washed three times with DMEM-10 or RPMI-
10 medium. After the ﬁnal wash, the cells were ﬁltered
through nylon mesh, and counted using a hemocytometer
and tryphan blue.
2.8. Flow Cytometry Experiments. I no r d e rt om e a s u r et h e
degree of DC maturation induced by α-GalCer and α-C-
GalCer, freshly isolated splenocytes from BALB/c mice were
ﬁrst incubated for 15 minutes at 4◦C with unlabeled anti-
mouse Fcγ III/II receptor mAb clone, 2.4G2 (PharMingen,
San Diego, CA) in staining buﬀer (PBS containing 1%
FBS and 0.1%NaN3) to block Fc receptors. Next, the cells
were surface stained with PE-conjugated anti-CD11c mAb
clone, HL3, and FITC-conjugated anti-CD86 mAb clone,
GL1, FITC-conjugated anti-CD40 mAb clone, HM40-3, or
syngeneic MHC-class II-speciﬁc FITC-conjugated anti-IAd
mAb clone, AMS-32.1 (all PharMingen, San Diego, CA) in
staining buﬀer for 30 minutes at 4◦C. After two washes
in staining buﬀer, the cells were then analyzed using a
FACSCalibur instrument (Becton Dickson, San Diego, CA)
with CELLQuest software (Becton Dickson, San Diego, CA).
Next, in order to speciﬁcally detect Vα14i NKT cells,
we ﬁrst loaded mouse CD1d-IgG1 dimer X molecules
(PharMingen, Sand Diego, CA) with a 10–20-fold molar
excessofα-GalCerovernightin1XPBSatroomtemperature.
After preparation of splenocytes and liver lymphocytes, we
incubated the cells with the loaded dimers for 60 minutes in
staining buﬀer at 4 degrees Celsius (after Fc receptor block),
using 4μg of loaded dimer for every 1 × 106 cells stained.
Next, after washing the cells once with staining buﬀer, we
surface stained the cells with FITC-labeled anti-CD3ε mAb
clone,145-2C11,andPE-labeledantimouseIgG1 clone,A85-
1 (both PharMingen, San Diego, CA) for 30 minutes in
staining buﬀer at 4 degrees Celsius. Finally, after washing the
stained cells twice with staining buﬀer, we analyzed them by
FACS as detailed above.
Finally, in order to measure the TCRβ usage of Vα14i
N K Tc e l l sb e f o r ea n da f t e ri nv i v oα-GalCer or α-C-GalCer
stimulation, we ﬁrst incubated splenocytes and liver lym-
phocytes with unlabeled antimouse Fcγ III/II receptor mAb
clone, 2.4G2 (PharMingen, San Diego, CA) and unlabeled
streptavidin (Molecular Probes, Eugene, OR) for 15 minutes
in staining buﬀe ra t4d e g r e e sC e l s i u si no r d e rt ob l o c kF c
receptors and surface biotin molecules. After washing the
cells twice with staining buﬀer, we incubated the cells with α-
GalCer-loaded dimers in the manner indicated above. After
dimer incubation, we surface stained the cells with FITC-
labeled anti-CD3ε mAb clone, 145-2C11, and either biotin-
labeled anti-Vβ8.1/8.2 clone, MR5-2, biotin-labeled anti-
Vβ7 clone, TR310, or biotin-labeled anti-Vβ2, clone B20.6
(all PharMingen, San Diego, CA) for 30 minutes in staining
buﬀer at 4 degrees Celsius, followed by two washes with
staining buﬀer. We then stained the cells with PE-labeled
antimouse IgG1 clone A85-1 and APC-labeled streptavidin
(both from PharMingen, San Diego, CA) for 30 minutes in
staining buﬀer at 4 degrees Celsius. Finally, after washing the
cells twice with staining buﬀer, we analyzed them by FACS as
detailed above.
3. Results
3.1. IL-12 Is a Key Factor in the Antimalarial Activity of
Both α-C-GalCer and α-GalCer. In a previous study, we
showed that α-C-GalCer’s ability to stimulate prolonged
IFN-γ production is abrogated in the absence of IL-12 [6].
Since IFN-γ is required for α-C-GalCer’s anti-malaria eﬀect,
we wanted to see if its superior therapeutic activity against
malaria liver stages was abrogated in the absence of IL-12 as
well. To address this issue, we ﬁrst treated both WT and IL-
12-deﬁcient mice with equal doses of either glycolipid three4 Journal of Biomedicine and Biotechnology
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Figure 2: α-C-GalCer’s superior therapeutic activity against malaria liver stages requires IL-12 and NK cells. (a) Groups of 5 WT or IL-
12-deﬁcient BALB/c mice were treated intraperitoneally (i.p.) with 1μg of either α-C-GalCer or α-GalCer or with nothing 3 days before
challenge intravenously with live P. yoelii sporozoites, and then checked for malaria liver stage development. The results are expressed as the
average +/− SD of 5 mice. (b) Groups of 5 WT C57BL/6 mice were treated i.p. with PBS or anti-asialoGM1 antibody 1 day prior to i.p.
injection with 1μgo fα-C-GalCer or α-GalCer, or with nothing. Three days later the mice were challenged with live P. yoelii sporozoites, and
then checked for malaria liver stage development. The results are expressed as the average +/− SD of 5 mice. The data shown come from one
of three experiments with similar results.
days before challenge with sporozoites, and then measured
malaria liver stage development. As expected, in WT mice
α-C-GalCer suppressed liver stage development to a much
greater degree than α-GalCer; however, in IL-12-deﬁcient
mice the anti-malaria activity of both glycolipids was totally
abolished (Figure 2(a)). Thus, IL-12 is a key factor not only
driving α-C-GalCer’s superior antimalarial eﬀect, but also
mediating the antiplasmodial eﬀect of both glycolipids.
3.2. α-C-GalCer’s Enhanced Antimalarial Response Requires
t h eP r e s e n c eo fN KC e l l s .Our ﬁnding that α-C-GalCer’s
superior antimalarial activity requires IL-12 (Figure 2(a)),
which is required for optimal IFN-γ production by NK cells
following glycolipid administration [6], strongly suggests
that NK cells are also required for α-C-GalCer’s supe-
rior antimalarial activity. To assess the role of NK cells
in α-GalCer- and α-C-GalCer-mediated protection against
malaria, we pretreated mice with anti-asiaoloGM1 antibody,
which is known to selectively deplete NK cells [12], or
with PBS, and one day later treated the mice with equal
doses of α-GalCer or α-C-GalCer, or with nothing. Three
days after glycolipid treatment, we challenged the mice with
sporozoites and then measured liver stage development as
before. We found that in nondepleted PBS-treated control
mice, α-C-GalCer exhibited better antimalarial activity than
did α-GalCer, as expected. In contrast, we observed an
abrogation of α-C-GalCer’s superior antimalarial activity in
mice depleted of NK cells with anti-asialoGM1 antibody
(Figure 2(b)). This result strongly suggests that α-C-GalCer’s
superiorantimalarialeﬀectstemsfromitsabilitytostimulate
enhanced IL-12 production, which then triggers NK cells to
produce more IFN-γ needed to suppress malarial liver stage
development.
3.3. α-C-GalCer’s Enhanced Antimalarial Response Does Not
Involve the Th2 Cytokines IL-4 and IL-10. In an earlier study,
we and others showed that mice injected with α-C-GalCer
produce a far less IL-4 than did those injected with α-
GalCer [6, 8]. Given that IL-4 is a Th2 cytokine with known
inhibitory activity against Th1 cytokines [13], we wereJournal of Biomedicine and Biotechnology 5
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Figure 3: α-C-GalCer’s superior antimalarial activity does not involve IL-4 or IL-10. (a) Groups of 5WT or IL-4-deﬁcient BALB/c mice, or
(b) groups of 5WT or IL-10-deﬁcient C57BL/6 mice, were treated i.p. with 1μg of either α-C-GalCer or α-GalCer or with nothing 3 days
before challenge with live P. yoelii sporozoites, and then checked for malaria liver stage development. The results are expressed as the average
+/− SD of 5 mice. The data shown come from one of three experiments with similar results.
curious to see if α-C-GalCer’s enhanced therapeutic activity
against diseases ameliorated by Th1 cytokines stems from
its ability to stimulate lower amounts of IL-4. To address
this issue, we injected both WT mice and mice deﬁcient in
IL-4 with equal doses of α-GalCer or α-C-GalCer, or with
nothing, and 3 days later challenged them with live P. yoelii
sporozoites.Forty-twohoursafterthechallenge,weobtained
livers from all the mice and determined the degree of malaria
liver stages that developed by way of quantitative real-time
RT-PCR. We found that the ability of α-C-GalCer to better
inhibit liver stages was the same in both IL-4-deﬁcient mice
and WT mice (Figure 3(a)). This result indicates that α-C-
GalCer’s superior antimalarial activity does not involve its
reduced IL-4 production.
Another Th2 cytokine known to be produced following
α-GalCer injection in mice is IL-10 [14, 15]. One of the
important eﬀects of IL-10 is the direct inhibition of IL-12
production by APCs, and the consequent downregulation of
Th1-type responses [13, 16, 17]. Given IL-10’s production
consequent to glycolipid injection in mice, and its inhibitory
aﬀect on Th1-type responses, we wanted to see if IL-10 plays
ar o l ei nα-C-GalCer’s enhanced therapeutic activity against
diseases ameliorated by Th1 cytokines. To address this issue,
we injected IL-10-deﬁcient mice and WT mice with equal
doses of α-GalCer or α-C-GalCer, or with nothing, and 3
days later challenged them with live sporozoites for a liver
stage protection experiment. As with IL-4 deﬁcient mice, we
found that IL-10-deﬁcient mice injected with α-C-GalCer
inhibited malarial liver stages better than those injected
with α-GalCer—the same as WT mice (Figure 3(b)). Thus,
it appears that IL-10 also plays no role in α-C-GalCer’s
enhanced antimalarial activity relative to α-GalCer.
3.4. α-C-GalCer Induces a Prolonged In Vivo Maturation of
DCs Compared to α-GalCer. In a previous study, we showed
that CD8α+ DCs are the cells responsible for producing IL-
12 in response to α-GalCer and α-C-GalCer injection, and
that depletion of these cellsresults in attenuated downstream
IFN-γ production by NK cells [7]. Given the importance
of DCs in the in vivo physiological response to α-GalCer
and α-C-GalCer, we wanted to see how these two glycolipids
aﬀect these cells in vivo in WT mice. To address this issue we
looked at the ability of α-GalCer and α-C-GalCer to induce
maturation of DCs by following the expression patterns of6 Journal of Biomedicine and Biotechnology
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Figure 4: α-C-GalCer induces a prolonged in vivo maturation of DCs compared to α-GalCer. Groups of 3WT mice were injected i.p. with
1μg α-GalCer or α-C-GalCer, or with nothing, and 2, 6, or 24 hours later splenocytes were collected and subjected to FACS analysis. CD11c+
cells were gated and analyzed for their levels of (a) MHC class II, (b) CD86, and (c) CD40 at the diﬀerent time points after glycolipid
administration. Also shown are isotype control stainings obtained from the maximally activated, 24-hour, α-GalCer-treated splenocyte
populations, gated on CD11c+ cells. The numbers next to each histogram tracing represent the mean ﬂuorescence intensity for that tracing.
The data shown come from one of four experiments with similar results.
various surface markers known to be upregulated during DC
maturation, namely, MHC class II, CD86, and CD40. More
speciﬁcally,weinjectedWTmicewithα-GalCer,α-C-GalCer,
or nothing, and 2, 6, and 24 hours later obtained splenocytes
forFACSanalysisofcellscoexpressingCD11candMHCclass
II, CD86, or CD40.
We found that the ﬁrst marker to show upregulation on
CD11c+ DCs after injection of either glycolipid was MHC
class II. α-GalCer-treated mice showed increased expression
of this marker as soon as 2 hours after injection, while α-
C-GalCer-treated mice showed increased expression 6 hours
after injection (Figure 4(a)). By 24 hours posttreatment, we
saw the highest MHC class II expression on CD11c+ DCs
frommiceinjectedwitheitherα-GalCerorα-C-GalCer, with
α-GalCer-treated mice expressing slightly more marker than
α-C-GalCer-treated mice (Figure 4(a)).
The next marker to show upregulation after glycolipid
injectionwasCD86.Inα-GalCer-treatedmice,CD86expres-
sion ﬁrst started showing an increase at 6 hours postinjec-
tion; whereas in α-C-GalCer-treated mice this marker did
not show increased expression until 24 hours postinjection
(Figure 4(b)). Again, as with MHC class II, we observed
the highest expression of CD86 24 hours after injection
of α-GalCer or α-C-GalCer, with α-GalCer-treated mice
expressing more marker than α-C-GalCer-treated mice at
this time point (Figure 4(b)).
Finally, the last DC marker to show upregulation follow-
ing glycolipid injection was CD40. In both α-GalCer- and α-
C-GalCer-injected mice, increased expression of this marker
was only observed 24 hours after treatment. At 2 and 6
hours postglycolipid injection, CD40 expression on DCs was
the same as untreated controls (Figure 4(c)). Interestingly,
at 24 hours postinjection the expression levels of CD40 on
DCsfrombothα-GalCer-andα-C-GalCer-treatedmicewere
more or less the same, in contrast to MHC class II and CD86
(Figure 4(c)). Overall, the upregulation data indicates that
α-GalCer induces a faster maturation of CD11c+ DCs than
does α-C-GalCer, which appears to induce a more prolonged
maturation of this cell type.
3.5. α-C-GalCer Induces a Slower and Shorter In Vivo Down-
regulationofVα14iTCRsandaGreaterInVivoProliferationof
Vα14iNKTCellsComparedtoα-GalCer. An umbe ro fr ec e nt
studies have shown that Vα14i NKT cells proliferate in vivo
following injection of α-GalCer [18–21]. This proliferation
is accompanied by early downregulation of Vα14i TCRs and
NK1.1 on the surface of NKT cells, followed by reappearance
of these markers two days later. A ﬁnding from earlier studies
that α-C-GalCer stimulates less cytokine production by NKT
cells than α-GalCer [6, 8] suggests that α-C-GalCer is a
weaker NKT cell stimulus than α-GalCer. To see if α-C-
GalCer also stimulates poorer proliferation of NKT cells
when compared to α-GalCer, we injected WT mice with
equal doses of either glycolipid, and 5, 24, 48, 72, 120, and
168 hours later obtained splenocytes and liver lymphocytes
for FACS analysis of Vα14i NKT cells. To detect Vα14i NKT
cells we made use of recently developed mouse CD1d-IgG1
dimers,which,whenloadedwithα-GalCer,stainVα14iNKT
cells [22].
We found that Vα14i NKT cells from α-GalCer-treated
mice rapidly downregulated their TCRs, becoming unde-
tectableinbothspleenandliverby5hours,andremainingso
at 24 hours (Figure 5(a)). Not until 48 hours did Vα14i NKT
cells from α- G a l C e r - t r e a t e dm i c eb e c o m ed e t e c t a b l ea g a i ni nJournal of Biomedicine and Biotechnology 7
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Figure 5: α-C-GalCer induces a slower and shorter in vivo downregulation of Vα14i TCRs and a greater in vivo proliferation of Vα14i NKT
cells compared to α-GalCer. (a) Groups of 2WT C57BL/6 mice were injected i.p. with 1μgo fα-GalCer or α-C-GalCer, and 0, 5, 24, 48,
72, 120, and 168 hours later splenocytes and liver lymphocytes were isolated and stained with α-GalCer-loaded mouse CD1d-IgG1 dimers
to assess the level of Vα14i NKT cells present. The numbers shown in the individual panels represent the percentage of Vα14i NKT cells
present in the gated lymphocyte population. The data shown are representative of three independent experiments. (b) The average absolute
numbers of Vα14i NKT cells in the spleens and livers of α-GalCer- and α-C-GalCer-treated mice at the various time points were calculated
according to the following equation: (percentage of Vα14i NKT cells in the gated lymphocyte population)∗(percentage of total isolated cells
represented by the gated lymphocyte population)∗(total number of isolated cells). The data shown are the average values calculated from
three independent experiments +/− SE.
both spleen and liver. At this time point the cells returned
to levels comparable to that detected prior to injection,
and remained so at 72, 120, and 168 hours postinjection
(Figure 5(a)).
In contrast to α-GalCer, Vα14i NKT cells from mice
treated with α-C-GalCer exhibited a slower and shorter TCR
downregulation, with small percentages of cells still present
at 5 hours in both spleen and liver (Figure 5(a)). At 24 hours
the cells were almost completely undetectable, but started
reappearing at 48 hours, although at lower levels than that
detected prior to injection (Figure 5(a)). Strikingly, at 72
hours the levels of Vα14i NKT cells in the spleens and livers
of α-C-GalCer-treated mice were greatly increased over that
observed prior to injection. In the spleen, the percentage of
cells was approximately 10 times higher than that observed
at the start; similarly, in the liver the percentage was about 3
times higher (Figure 5(a)). At 120 hours, the levels of Vα14i
NKT cells started to come down in both the spleen and
liver, but still remained higher than that observed prior to
injection. By 168 hours, the percentages continued to come
down, approaching baseline in the liver, but remaining high
in the spleen (Figure 5(a)).
Using the percentages of Vα14i NKT cells we were
able to follow the overall proliferative response of the cells
stimulated by the glycolipids. We found that the overall
pattern of Vα14i NKT cell expansion was the same for
both glycolipids, with peak cell numbers occurring 72
hours postinjection followed by a return towards baseline
(Figure 5(b)). Surprisingly, we found that α-C-GalCer stim-
ulated a far greater expansion of Vα14i NKT cells in both
spleen and liver than did α-GalCer. The diﬀerence was most
striking at 72 hours when the numbers of Vα14i NKT cells
in the spleens and livers of α-C-GalCer-treated mice were
approximately 5 times higher than those in α-GalCer-treated
mice(Figure 5(b)).Overall,thisdataindicatesthatdespiteits
poor ability to stimulate cytokine production by NKT cells
[6], α-C-GalCer is a better in vivo stimulus for Vα14i NKT
cell proliferation than α-GalCer.8 Journal of Biomedicine and Biotechnology
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Figure 6: TCRβ usage does not aﬀect in vivo Vα14i NKT cell activation stimulated by α-GalCer or α-C-GalCer. Groups of 2 WT C57BL/6
were injected i.p. with 1μgo fα-GalCer or α-C-GalCer, or with nothing, and 72 hours later splenocytes and hepatic lymphocytes were
isolated and stained for Vα14i NKT cells using α-GalCer-loaded mouse CD1d-IgG1 dimers, as well as for Vβ8.1/8.2, Vβ7, and Vβ2. Vα14i
NKT cells were gated, and FACS analyzed for the three diﬀerent Vβ gene segments. The numbers shown represent the percentage of cells
expressing the indicated Vβ segment. The data shown comes from one of two independent experiments with similar results.
3.6. TCRβ Usage Does Not Aﬀect In Vivo Vα14i NKT
Cell Activation Stimulated by α-GalCer or α-C-GalCer. Two
recent studies show that TCRβ usage by Vα14i NKT cells
aﬀects the avidity of Vα14i TCRs for CD1d-glycolipid
complexes [22, 23]. In particular, they indicate that TCRβ
chains encoded by the Vβ8.2 gene segment confer higher
avidity to Vα14i TCRs than Vβ7o rV β2, and that gly-
colipid ligands preferentially stimulate these higher avidity
cells. Despite these ﬁndings, our data showing a complete
disappearance of Vα14i NKT cells by 24 hours post-α-
GalCer or α-C-GalCer injection (Figure 5(a)) suggests that
in vivo both glycolipids stimulate all Vα14i NKT cells
regardless of their TCRβ usage. To conﬁrm this suspicion,
we treated WT mice with α-GalCer, α-C-GalCer, or with
nothing, and 72 hours later obtained splenocytes and liver
lymphocytesforstainingwithCD1d-IgG1dimerloadedwith
α-GalCer. In addition to dimer staining, we also stained
the cells for Vβ8.1/8.2, Vβ7, and Vβ2 to see if the distri-
bution Vα14i NKT cells changes after glycolipid-mediated
stimulation. More speciﬁcally, if α-GalCer or α-C-GalCer
preferentially stimulates the higher avidity Vβ8.2-containing
NKT cells in vivo, then there should be an increase in
the proportions of these cells in the expanded NKT cell
population that results after glycolipid-induced prolifera-
tion. We found that there was no diﬀerence in the pro-
portions of TCRβ usage by Vα14i NKT cells before or
after stimulation with α-GalCer or α-C-GalCer (Figure 6).
Prior to glycolipid administration about 50% of Vα14i
NKT cells in the livers and spleens of mice expressed
Vβ8.1/8.2, while about 15% expressed Vβ7 and 3-4%
expressed Vβ2. These proportions did not change after α-
GalCer- or α-C-GalCer-induced proliferation (Figure 6). In
all, these results suggest that TCRβ usage does not aﬀect in
vivo Vα14i NKT cell activation stimulated by α-GalCer or
α-C-GalCer.
4. Discussion
Thecurrentstudyfurtherdeﬁnesthephysiologicmechanism
by which α-C-GalCer exhibits its superior antimalarial
activity when compared to its structurally similar analog
α-G a l C e r .A sr e p o r t e dp r e v i o u s l yα-C-GalCer’s enhanced
antimalarial eﬀect appears to stem from prolonged down-
stream IFN-γ production by NK cells requiring IL-12 [6].
This requirement for IL-12 is reconﬁrmed in the present
study by our results showing the abrogation of α-C-GalCer’s
enhanced therapeutic eﬀect against malaria liver stages in
mice lacking IL-12 (Figure 2(a)). The current study also
deﬁnitively deﬁnes the important role of NK cells in the
mechanism of α-C-GalCer’s enhanced antimalarial eﬀect.
Our ﬁnding that NK cell depletion abrogates α-C-GalCer’s
superior antimalarial activity when compared to α-GalCer
attests to the key role these cells play (Figure 2(b)). In
addition, despite a previously reported ﬁnding that α-C-
GalCer stimulates less IL-4 than α-GalCer [6, 8], the ability
of α-C-GalCer to stimulate diminished production of Th2
cytokines like IL-4 and IL-10 has no aﬀect on its superior
therapeutic activity relative to α-GalCer (Figure 3). Taken
together, these data, along with our prior results showing
that CD8α+ DCs are the cells responsible for producing IL-
12 in response to glycolipid injection [7], indicate that α-C-
GalCer’s superior antimalarial activity stems from its ability
to stimulate prolonged IL-12 production by DCs thereby
resulting in enhanced downstream IFN-γ production by NK
cells, and enhanced protection (Figure 7).
Our previous ﬁnding that α-C-GalCer stimulates pro-
longed IL-12 by DCs [7] correlates with our current ﬁnding
that α-C-GalCer induces prolonged maturation of DCs after
injection into mice (Figure 4). The fact that DCs mature at
a slower rate after α-C-GalCer administration than after α-
GalCer administration implies that the NKT cell inputs intoJournal of Biomedicine and Biotechnology 9
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Figure 7: Mechanism of α-C-GalCer’s enhanced therapeutic eﬀect
against malarial liver stages: (1) α-C-GalCer presented by CD1d
molecules expressed on APCs stimulates, (2) enhanced (+) prolif-
eration by Vα14i NKT cells relative to α-GalCer, and (3) enhanced
(+) activation and IL-12 release by APCs compared to α-GalCer,
which (4) induces augmented IFN-γ production by NK cells. This
increased IFN-γ is responsible for (5) the better protection against
malarial liver stages exhibited by α-C-GalCer.
α-C-GalCer-bearing DCs are weaker than those delivered
to α-GalCer-bearing DCs. These weaker inputs might stem
from a lower aﬃnity interaction between the Vα14i TCR
and the CD1d-α-C-GalCer complex. In light of studies
demonstrating NKT cell TCR downregulation hours after
encounter with α-GalCer-bearing APCs [19–21], as well as
other studies showing that high aﬃnity interactions result
in faster and greater TCR downregulation [24, 25], the
weaker Vα14i TCR:CD1d-α-C-GalCer interaction would be
expected to result in slower and lesser downregulation of
Vα14i TCRs on NKT cells than that seen with α-GalCer.
Indeed, our experiment looking at the disappearance and
reappearance of Vα14i NKT cells after α-GalCer or α-
C-GalCer administration demonstrated precisely this phe-
nomenon (Figure 5). As a consequence of shorter/lesser TCR
downregulation, longer contact between NKT cells and α-
C-GalCer-bearing DCs probably occurs, which would result
in a temporal summation of NKT cell inputs by DCs that
might exceed that achieved by α-GalCer-bearing DCs, which
receivestronger-butshorter-livedinputsfromNKTcellsdue
to the higher aﬃnity interaction between the Vα14i TCR and
the CD1d-α-GalCer complex. Since glycolipid-induced IL-
12 production by DCs requires contact with NKT cells [26–
31], α-C-GalCer’s ability to stimulate prolonged IL-12 might
stem from longer contact time between NKT cells and α-C-
GalCer-bearing DCs.
In addition to stimulating a slower and shorter down-
regulation of TCRs on Vα14i NKT cells, the interaction
between CD1d-α-C-GalCer complexes and Vα14i TCRs also
stimulates a greater in vivo expansion of Vα14i NKT cells
compared to α-GalCer (Figure 5). This result is surprising
because earlier data from us and others demonstrating that
α-C-GalCerstimulateslesscytokineproductionbyNKTcells
than α-GalCer [6, 8] implies that α-C-GalCer is a weaker
agonist for NKT cells. It is likely that the striking diﬀerences
we observed in the abilities of α-GalCer and α-C-GalCer to
induce cytokine synthesis and cellular expansion by NKT
cells are the result of diﬀerential TCR signal transduction
events, which probably stem from the diﬀerence in aﬃnities
between the Vα14i TCR:CD1d-α-GalCer interaction and the
Vα14i TCR:CD1d-α-C-GalCer interaction.
This situation is analogous to a previous study showing
that a partial T cell agonist incapable of stimulating early
T cell activation events was capable of stimulating later
events, such as proliferation, to the same degree or better as
the full agonist [32]. These ﬁndings were explained by the
so-called kinetic proofreading model for T cell activation,
which proposes that while early T cell activation events
depend on the aﬃnity of TCR:MHC-peptide interactions,
later T cell activation events depend more on the temporal
summation of successive TCR signals delivered by MHC-
peptidecomplexesseriallyengagingdiﬀerentTCRsovertime
[24, 32–36]. Based on this model, it is possible that α-
C-GalCer is a partial NKT cell agonist, whose ability to
stimulate enhanced Vα14i NKT cell expansion is due to
enhanced temporal summation of APC inputs by NKT cells
made possible by slower and shorter TCR downregulation
and prolonged contact between NKT cells and α-C-GalCer-
bearing APCs. While more research is needed to verify this
mechanism, it is interesting to note that TCRβ usage does
not appear to eﬀect α-C-GalCer’s stimulation of NKT cells
(Figure 6) despite two recent studies showing that TCRβ
chains encoded by the Vβ8.2 gene segment confer higher
avidity to Vα14i TCRs than Vβ7o rV β2, and that glycolipid
ligands preferentially stimulate these higher avidity cells [22,
23].
5. Conclusions
We have previously shown that the C-glycoside analog of α-
GalCer, α-C-GalCer, displays a superior inhibitory activity
against the liver stages of the rodent malaria parasite P. yoelii.
In the present study, we not only conﬁrmed that IL-12 is a
key factor that mediates the antiplasmodial activity of both
glycolipids, but also deﬁned the important role of NK cells
as mediators of α-C-GalCer’s superior eﬀect. We found that
theTh2cytokinesIL-4andIL-10arenotinvolved. Moreover,
we demonstrated a diﬀerential activity of α-C-GalCer in its
stimulation of DCs as compared to α-GalCer, and correlated
this with an enhanced proliferative response of Vα14i NKT
cells to α-C-GalCer. Finally, we showed that Vβ usage does
not inﬂuence the response of Vα14i NKT cells to either
glycolipid.
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